Advances in Functional Proteomics Spell Speedier Drug Discovery

Proteomics research is undergoing excessive growth. Nearly every major biotech and pharmaceuticals firm has implemented a proteomics program. Functional proteomics, the study of protein function and identification of protein interactions, is playing a major role in drug discovery, biomarkers, molecular diagnostics, and antibody therapies. A primary goal of biomedical research is discovering how cells respond to genetic instructions by creating thousands of protein variations and observing their reactions.

Frost & Sullivan (http://www.ti.frost.com) finds that the study Functional Proteomics provides market drivers, technical challenges, and emerging enabling technologies in this space. It also describes a variety of results obtained using these technologies.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the Functional Proteomics, then send an e-mail to Melina Trevino - Corporate Communications at This email address is being protected from spambots. You need JavaScript enabled to view it. with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

"Functional proteomics is developing at a rapid pace to address a critical need in the discovery of drug targets, with the development of a single drug costing an average of $500 million, and only 30 percent of approved drugs recovering these costs," says Frost & Sullivan Research Analyst Katherine Austin. "To address this need, pharmaceuticals companies need to find out methods to collect large amounts of data to dissect the complex, disease-causing interactions between proteins within the cell, and between proteins in the extra-cellular environment."

Functional proteomic technologies enable identification of functions for uncharacterized human proteins, the discovery of other proteins with which they interact, and an understanding of their involvement in important disease pathways. Understanding cell-signaling pathways and the manner in which cells communicate will provide greater understanding of disease mechanisms, revealing potential drug targets that are more likely to succeed. After the development of drugs, pathway knowledge is critical in understanding the downstream effects of drug treatment. Enhanced knowledge of pathways will reduce side affects.

Unfortunately, proteins are far more complicated than DNA. Technical problems have plagued functional proteomic R&D on every front. Problems associated with functional proteomic technologies, such as protein arrays are also numerous.

"The development of various proteomic kits and targeted solutions is fraught with pitfalls, many of which deal with the vast range of chemical and physical properties of different proteins," explains Austin. "Some of these include the complexity of the protein-interaction map, a lack of standardization, which makes it difficult to compare or validate results from different laboratories, and a lack of protein-specific capture agents such as antibodies."

Before accepting functional proteomics as a standard, high throughput approach, technology developers need to address a number of challenges. There is a need for new tools and research strategies on all fronts, for protein expression, purification, screening, and measuring protein interactions. In addition, assay sensitivity– the ability to detect low-abundance proteins–need to be more, by following standard techniques that provide reliable and acceptable results for pharmaceuticals applications.

Functional Proteomics is part of the Technical Insights, Healthcare, and examines the following applications: drug discovery, biomarkers, molecular diagnostics and antibody therapies, enabling technologies: spectometry, microarrays, electrophoresis, immunohistochemistry, yeast and viral expression and identification, affinity chromatography, and immunohistochemistry. Interviews are available to the press.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...